Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 7/20 | 0.44 |
| ▸ | CCR3 | P51677 | 7/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12137589 | 1.00 | LMNA (0.58) | LMNAGAAKDM4EHRH1CCR3 | |
| SCHEMBL3728983 | 1.00 | LMNA (0.58) | LMNAGAAKDM4EHRH1CCR3 | |
| SCHEMBL627928 | 1.00 | LMNA (0.58) | LMNAGAAKDM4EHRH1CCR3 | |
| SCHEMBL890204 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL13154902 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL890201 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL12174930 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL12292181 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL13154957 | 0.88 | DPP4 (0.44) | LMNAGAAKDM4ETSHRALDH1A1 | |
| SCHEMBL29038675 | 0.86 | LMNA (0.57) | LMNAGAAKDM4EHRH1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1873208-B2 | CURABLE COMPOSITION AND CURED ARTICLE EXCELLENT IN TRANSPARENCY | KANEKA CORP (JP) | 2024-10-09 | — | — | EP | disclosed |
| EP-1873208-B1 | CURABLE COMPOSITION AND CURED ARTICLE EXCELLENT IN TRANSPARENCY | KANEKA CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8759435-B2 | Curable composition and cured article excellent in transparency | KANEKA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| EP-1832626-B1 | CURABLE COMPOSITION | KANEKA CORP (JP) | 2012-06-13 | — | — | EP | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
| US-7781525-B2 | Curable composition | KANEKA CORPORATION (JP) | 2010-08-24 | — | — | US | disclosed |
| US-20090087635-A1 | Curable Composition and Cured Article Excellent in Transparency | KANEKA CORPORATION (JP) | 2009-04-02 | — | — | US | disclosed |
| US-20080188624-A1 | Curable Composition | KANEKA CORPORATION (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1873208-A1 | CURABLE COMPOSITION AND CURED ARTICLE EXCELLENT IN TRANSPARENCY | Kaneka Corporation (JP) | 2008-01-02 | — | — | EP | disclosed |
| EP-1832626-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | LMNA 3118/4885GAA 223/4885KDM4E 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.